WINNIPEG, MANITOBA -- (Marketwired) -- 05/26/14 -- Miraculins Inc. (TSX VENTURE: MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, has closed its recently announced private placement offering (the "Offering") with aggregate gross proceeds to the Company of $260,000 from the sale of 2,600,000 units ("Units") at a price of $0.10 per Unit. Each Unit is comprised of one common share of the Company (a "Share") and one Share purchase warrant (a "Warrant").
Each whole Warrant entitles the holder to purchase one Share at a price of $0.15 per Share for a period of twenty-four months from the date the Warrant is issued. The Shares and Warrants will be restricted from transfer for a period of four months and a day from the date hereof in accordance with applicable securities laws. The net proceeds of the Offering shall be used for general corporate purposes.
One finder assisted the Company by introducing a subscriber to the Offering and was paid a finder's fee of 10% of the total subscription proceeds received from the subscriber introduced to the Company by the finder.
A director of the Company, James Mellon, through an investment company that he controls, subscribed for 1,450,000 Units for gross proceeds of $145,000. In addition, the wife of another Company director subscribed for 50,000 Units for gross proceeds of $5,000. These transactions are "related party transactions" for the purposes of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on an exemption from the minority approval and formal valuation requirements of MI 61-101 due to the fact that the value of these transactions does not represent greater than 25% of the market capitalization of the Company.
The closing of the Offering is subject to the final approval of the TSX Venture Exchange.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1596 (FAX)
info@miraculins.com
www.miraculins.com
